Ahmad Norfazilah, Nawi Azmawati Mohammed, Jamhari Mohd Nazrin, Nurumal Siti Rohani, Mansor Juliana, Zamzuri Mohd 'Ammar Ihsan Ahmad, Yin Teh Li, Hassan Mohd Rohaizat
Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia.
Ministry of Health, Malaysia, Federal Government Administrative Centre, 62590 Putrajaya, Malaysia.
Iran J Public Health. 2022 May;51(5):967-977. doi: 10.18502/ijph.v51i5.9412.
Post-exposure prophylaxis (PEP) is an effective method for preventing rabies, a highly fatal infection in exposed persons. Malaysia is currently using the purified Vero cell rabies vaccine (PVRV). Nonetheless, there are other commercially available vaccine types and regimens. This systematic review aimed at comparing the effectiveness of the different PEP vaccines, regimens and routes of administration among Asian populations.
We systematically reviewed the PubMed and Web of Science databases for articles reporting on the effectiveness of PEP vaccination against rabies among Asian populations between 2015 and 2019.
Our search identified 11 relevant studies. Majority of study either used PCECV or PVRV type of vaccine, with different regimes and method. All are non-inferior to the other. Most of the studies recorded adequate response by Day 14 of vaccination. Nonetheless, the intradermal (ID) vaccination used minimal volume of vaccine used in all settings, thus cost less and the concurrent administration of RIG to the wound(s) doesn't affect the RVNA GMT response.
PCECV, using either the Essen or Zagreb regimen, might be a useful alternative for the healthy population in the context of PVRV shortage, especially during an outbreak. Use of the Zagreb or Thai Red Cross (TRC) regimens can be considered (either PVRV or PCECV), as both demonstrate good immunogenic outcomes in Asian populations.
暴露后预防(PEP)是预防狂犬病的有效方法,狂犬病对于暴露者来说是一种高度致命的感染。马来西亚目前使用纯化的Vero细胞狂犬病疫苗(PVRV)。尽管如此,还有其他可商购的疫苗类型和接种方案。本系统评价旨在比较亚洲人群中不同PEP疫苗、接种方案和给药途径的有效性。
我们系统检索了PubMed和Web of Science数据库,以查找2015年至2019年间报道亚洲人群中PEP疫苗接种预防狂犬病有效性的文章。
我们的检索确定了11项相关研究。大多数研究使用的是鸡胚细胞狂犬病疫苗(PCECV)或PVRV类型的疫苗,接种方案和方法各不相同。所有这些都不劣于其他方案。大多数研究在接种后第14天记录到了足够的反应。尽管如此,皮内(ID)接种在所有情况下使用的疫苗量最少,因此成本较低,并且同时向伤口注射狂犬病免疫球蛋白(RIG)不会影响狂犬病病毒中和抗体(RVNA)几何平均滴度(GMT)反应。
在PVRV短缺的情况下,尤其是在疫情爆发期间,使用埃森或萨格勒布方案的PCECV可能是健康人群的一种有用替代方案。可以考虑使用萨格勒布或泰国红十字会(TRC)方案(PVRV或PCECV均可),因为这两种方案在亚洲人群中均显示出良好的免疫原性结果。